Scarica l'app Stockscreener
161.13
0.55%
0.88
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
Jazz Pharmaceuticals plc (JAZZ) Advances Rare Cancer Portfolio with First CNS Glioma Therapy Approval - MSN
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates - sharewise.com
Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology (NASDAQ:JAZZ) - Seeking Alpha
Jazz Pharmaceuticals touts Phase 3 zanidatamab OS win in HER2+ GEA, eyes FDA sBLA in H1 - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Is Down 5.7% After Strong Ziihera Phase 3 DataHas The Bull Case Changed? - simplywall.st
Jazz Pharmaceuticals stock price target raised to $263 from $247 at BofA - Investing.com UK
Why Jazz Pharmaceuticals plc stock remains resilient2025 Earnings Impact & Daily Chart Pattern Signals - ulpravda.ru
What sentiment indicators say about Jazz Pharmaceuticals plc stockJuly 2025 WrapUp & Technical Confirmation Trade Alerts - ulpravda.ru
Jazz pharmaceuticals appoints Thomas Riga as chief business officer By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals names Thomas Riga as Chief Business Officer - StreetInsider
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer, Effective January 1, 2026 - MarketScreener
Should I hold or sell Jazz Pharmaceuticals plc stock in 2025Weekly Trend Summary & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Positive Ziihera Phase 3 Gastroesophageal Cancer Results - simplywall.st
Is Jazz Pharmaceuticals plc stock positioned well for digital economyInstitutional Holding Changes & Free Stop-Loss Planning for Your Portfolio - ulpravda.ru
Why Is Jazz Pharmaceuticals Stock Trading Higher Today?Jazz Pharmaceuticals (NASDAQ:JAZZ) - Benzinga
Jazz’s Ziihera Stakes Claim As Frontline Choice In HER2+ Gastroesophageal Cancer - Citeline News & Insights
Jazz Pharmaceuticals stock shows promise with positive Phase 3 data By Investing.com - Investing.com Nigeria
Jazz Pharma stock falls after lowered full year guidance - MSN
Jazz boasts of first-line Ziihera data in gastroesophageal cancers - MSN
Jazz Pharmaceuticals stock falls after Phase 3 trial results By Investing.com - Investing.com South Africa
Baird reiterates Underperform rating on Jazz Pharmaceuticals stock at $209 By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals' Ziihera Therapy Significantly Extends Survival in GEA Patients - Intellectia AI
Jazz Pharmaceuticals announce positive efficacy from Ziihera phase 3 trial - MarketScreener
Jazz’s Ziihera shows unprecedented survival benefit in gastric cancer By Investing.com - Investing.com UK
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit - GlobeNewswire Inc.
Jazz Pharmaceuticals stock rating reiterated at Outperform by RBC Capital - Investing.com Nigeria
Psychedelic Drugs Market to Reach USD 9.20 Billion by 2033 | CAGR - openPR.com
Volume Summary: Will Jazz Pharmaceuticals plc stock deliver long term returnsDividend Hike & Consistent Income Trade Recommendations - moha.gov.vn
The Truth About Jazz Pharmaceuticals: Is Wall Street Sleeping On This Quiet Game-Changer? - AD HOC NEWS
How Jazz Pharmaceuticals Plc (JAZZ) Affects Rotational Strategy Timing - Stock Traders Daily
Jazz Pharmaceuticals stock falls after Phase 3 trial results - Investing.com
Reflecting On Pharmaceuticals Stocks’ Q3 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) - Yahoo Finance
Corient Private Wealth LLC Cuts Stock Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Reflecting On Pharmaceuticals Stocks' Q3 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) - Finviz
Pacer Advisors Inc. Sells 194,639 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After a Strong Year-to-Date Share Price Rally - simplywall.st
Jazz Pharmaceuticals (FRA:J7Z) EV-to-OCF : 9.16 (As of Dec. 21, 2025) - GuruFocus
Update Report: What sentiment indicators say about Jazz Pharmaceuticals plc stockIPO Watch & Risk Controlled Daily Trade Plans - moha.gov.vn
JAZZ SEC FilingsJazz Pharmaceuticals Plc 10-K, 10-Q, 8-K Forms - Stock Titan
211,185 Shares in Jazz Pharmaceuticals PLC $JAZZ Acquired by Wedge Capital Management L L P NC - MarketBeat
Published on: 2025-12-21 12:21:40 - Улправда
Volume Summary: Is Jazz Pharmaceuticals plc stock positioned well for digital economy2025 Fundamental Recap & AI Based Buy/Sell Signal Reports - ulpravda.ru
Perpetual Ltd Reduces Stock Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals (MEX:JAZZ) EV-to-OCF : 8.83 (As of Dec. 19, 2025) - GuruFocus
Jazz Pharmaceuticals (MIL:1JAZZ) EV-to-FCF : 10.20 (As of Dec. 19, 2025) - GuruFocus
Jazz Pharmaceuticals (MIL:1JAZZ) EV-to-OCF : 9.11 (As of Dec. 19, 2025) - GuruFocus
Resistance Check: Why Jazz Pharmaceuticals plc stock remains resilientChart Signals & Weekly Chart Analysis and Trade Guides - DonanımHaber
Is Jazz Pharmaceuticals plc stock cheap compared to fundamentalsBear Alert & Expert Approved Trade Ideas - Улправда
Is It Too Late To Consider Jazz Pharmaceuticals After Its Strong 2024 Share Price Rally? - Yahoo Finance
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Clinical momentum lifts biopharma stocks into year-end - BioWorld MedTech
3 Reasons JAZZ is Risky and 1 Stock to Buy Instead - Barchart.com
Jazz Pharmaceuticals to Participate in Upcoming Investor Events - PR Newswire
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Texas Permanent School Fund Corp - MarketBeat
Jazz Pharmaceuticals (JAZZ): Valuation Check After Positive Ziihera and Epidiolex Clinical Updates Boost Investor Interest - simplywall.st
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):